Compare Abeona Therapeutics Inc (ABEO) vs iShares 1 3 Year Treasury Bond ETF (SHY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs iShares 1 3 Year Treasury Bond ETF — how do they compare? Abeona Therapeutics Inc trades at $6.73 (market cap $373.32M), while iShares 1 3 Year Treasury Bond ETF trades at $81.85. The key difference: Abeona Therapeutics Inc is trading nearer its 52-week high, iShares 1 3 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| ABEO | SHY | |
|---|---|---|
Market Cap | $373.32M | — |
Sector | Health | Fixed Income |
52-Week High | $7.23 | $83.18 |
52-Week Low | $4.17 | $81.84 |
Enterprise Value | $228.22M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
SHY trades at $81.98 with minimal daily movement (+0.05%). Technical indicators show a bearish trend with moving averages signaling sell pressure, while oscillators remain neutral. The ETF maintains consistent dividend distributions of $0.24 per share quarterly. Recent bond market focus highlights investor interest in Treasury income products amid rising yield expectations and Federal Reserve policy uncertainty.
The outlook remains cautious given bearish technical signals and bond market volatility. Investment opportunity exists for income-focused investors seeking Treasury exposure, though risks include interest rate sensitivity and Fed policy shifts. Current market conditions favor defensive positioning with attention to yield curve movements.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About iShares 1 3 Year Treasury Bond ETF
SHY provides exposure to U.S. Treasury bonds with remaining maturities between one and three years. It is a low-risk, highly liquid ETF designed for capital preservation and short-term income, featuring 2026 top holdings across various Treasury Notes.
Read more on SHY →
